Palvella Therapeutics Initiates Phase 3 Trial for Breakthrough Microcystic LM Therapy

Deal News | Nov 07, 2024 | Agent Capital LLC

Palvella Therapeutics, a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, has dosed the first patient in a crucial Phase 3 clinical trial for its QTORIN 3.9% rapamycin anhydrous gel, intended to treat microcystic lymphatic malformations (microcystic LMs). With no FDA-approved therapies currently available for this rare, debilitating genetic disease, QTORIN rapamycin stands on the brink of becoming a pioneering treatment option. Endorsed by the FDA with designations like Breakthrough Therapy and Orphan Drug, this trial highlights significant advancements in addressing critical skin diseases. Concurrently, Palvella is collaborating on a merger with Pieris Pharmaceuticals in an all-stock transaction aimed at broadening their capabilities and market reach.

Sectors

  • Biopharmaceuticals
  • Healthcare

Geography

  • United States – The clinical trial for QTORIN rapamycin is being conducted across leading vascular anomaly centers in the U.S., and the article discusses implications for patients in the United States.

Industry

  • Biopharmaceuticals – The article centers on Palvella Therapeutics, which is developing QTORIN rapamycin, a biopharmaceutical product targeting rare genetic skin diseases.
  • Healthcare – The focus on microcystic lymphatic malformations and the effort to develop therapeutic interventions directly pertains to advancements in healthcare treatment for genetic conditions.

Financials

  • $2.6 million – Awarded by the FDA's Office of Orphan Products Development to support the SELVA study for QTORIN rapamycin.

Participants

NameRoleTypeDescription
Palvella TherapeuticsClinical-stage biopharmaceutical company; Target CompanyCompanyA company focused on developing treatments for serious, rare genetic skin diseases, presently conducting a Phase 3 trial for QTORIN rapamycin.
Agent Capital LLCPrivate Equity FirmCompanyThe PE firm backing Palvella Therapeutics, supporting the development of their pharmaceutical products.
Pieris Pharmaceuticals, Inc.Merger PartnerCompanyA biopharmaceutical company set to merge with Palvella in an all-stock transaction to expand their joint capabilities.
Joyce M. Teng, M.D., Ph.D.Principal InvestigatorPersonProfessor of Dermatology and Pediatrics at Stanford University, leading the SELVA Phase 3 clinical trial for Palvella Therapeutics.
U.S. Food and Drug Administration (FDA)Regulatory BodyGovernmentGranted Breakthrough Therapy, Fast Track, and Orphan Drug Designations for QTORIN rapamycin.